Trade and Access to Medicines
The Boston University Working Group on Trade Treaties and Access to Medicines was established in 2018 to advance an evidence-based understanding of the impacts of trade and investment treaties on access to medicines. The goal is to offer concrete policies and advice to help the trade and investment system be a tool in expanding global access to secure and affordable medicines.
The Working Group is a dynamic group of economists, legal scholars, medical scientists and policy analysts from around the world, which conducts empirical research exploring the relationship between treaties and pharmaceutical prices, political economy analyses of the challenges to domestic institutions in securing access to medicines and legal research on the prevalence of treaty terms increasing the global levels of intellectual property protection. Specific research projects include: research in on bilateral trade agreements and the price of biologics; global trade treaties and the price of insulin; and the ability to build local productive capacity in the pharmaceuticals industry in developing countries.
The Working Group also advances policy discourse at the World Trade Organization and at numerous regional and bilateral trade and investment treaties through direct engagement with policy makers, media, civil society and public dialogue.
Trade & Medicines News
A Way Forward for Equitable Pharmaceutical Access After COVID-19May 24, 2023
By Brook Baker and Rachel Thrasher COVID-19 exploded on a global stage dominated by an international legal and policy regime that instantiates closed science, intellectual property (IP) monopolies and privatized control over the testing, supply, price and distribution of life-saving health... [ More ]
From Business as Usual to Health for the Future: Challenging the Intellectual Property Regime to Address COVID-19 and Future PandemicsMay 24, 2023
COVID-19 has been met by an international legal and policy regime of closed science, intellectual property monopolies and privatized control over the testing, supply, price and distribution of life-saving health technologies. Despite the remarkable effectiveness of the currently available vaccines, [ More ]